Ivan Borbath
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.2%
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
Papers in
- Oncology 66
- Pancreatic and Hepatic Oncology Research 39
- Lung Cancer Research Studies 25
- Epidemiology 62
- Neuroendocrine Tumor Research Advances 56
- Co-authors
- Juan W. Valle (15 shared papers)Pascal R. Hammel (3 shared papers)Florence Huguet (3 shared papers)Catherine Lombard Bohas (12 shared papers)Dieter Hörsch (2 shared papers)Eric Van Cutsem (10 shared papers)Philippe B Ruszniewski (6 shared papers)Éric Raymond (7 shared papers)
- Journals
- Annals of Oncology (23 papers)European Journal of Cancer (10 papers)Neuroendocrinology (5 papers)The Lancet Oncology (4 papers)The Lancet. Gastroenterology & hepatology (4 papers)
- Partner nations
- BelgiumFranceUnited States
In The Last Decade
Ivan Borbath
137 papers receiving 22.5k citations
Ivan Borbath's Hit Papers
Peers
Comparison fields: 5 of 134
- Hepatology 8.2k
- Oncology 7.5k
- Cancer Research 2.8k
- Epidemiology 5.9k
- Pathology and Forensic Medicine 2.2k
Countries citing papers authored by Ivan Borbath
This map shows the geographic impact of Ivan Borbath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Borbath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Borbath more than expected).
Fields of papers citing papers by Ivan Borbath
This network shows the impact of papers produced by Ivan Borbath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Borbath. The network helps show where Ivan Borbath may publish in the future.
Co-authors
The 25 scholars most cited alongside Ivan Borbath, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 142 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2008 | 11056 |
| 2 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Hit paper breakdown → | 2018 | 2076 |
| 3 | Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2047 |
| 4 | Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib Hit paper breakdown → | 2016 | 818 |
| 5 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 699 |
| 6 | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma Hit paper breakdown → | 2017 | 554 |
| 7 | Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 538 |
| 8 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Hit paper breakdown → | 2012 | 485 |
| 9 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2022 | 436 |
| 10 | Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study Hit paper breakdown → | 2021 | 333 |
| 11 | 2015 | 315 | |
| 12 | 2017 | 266 | |
| 13 | Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline Hit paper breakdown → | 2022 | 222 |
| 14 | 2017 | 190 | |
| 15 | 2019 | 171 | |
| 16 | 2016 | 155 | |
| 17 | 2021 | 122 | |
| 18 | 1999 | 94 | |
| 19 | 2017 | 94 | |
| 20 | 2017 | 93 |
About Ivan Borbath
Ivan Borbath is a scholar working on Oncology, Epidemiology, Hepatology, Neurology and Cancer Research, having authored 142 papers that have together received 23.0k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (56 papers), Pancreatic and Hepatic Oncology Research (39 papers), Lung Cancer Research Studies (25 papers), Hepatocellular Carcinoma Treatment and Prognosis (18 papers), Neuroblastoma Research and Treatments (15 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Fibroblast Growth Factor Research (8 papers) and Gastrointestinal Tumor Research and Treatment (6 papers). The work is most often cited by research in Hepatology (8.2k citations), Oncology (7.5k citations), Cancer Research (2.8k citations), Epidemiology (5.9k citations) and Pathology and Forensic Medicine (2.2k citations). Ivan Borbath has collaborated with scholars based in Belgium, France and United States. Frequent co-authors include Juan W. Valle, Pascal R. Hammel, Florence Huguet, Catherine Lombard Bohas, Dieter Hörsch, Eric Van Cutsem, Philippe B Ruszniewski, Éric Raymond, Denis Michel Smith and Jean‐Luc Raoul. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Neuroendocrinology, The Lancet Oncology and The Lancet. Gastroenterology & hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.